AB-103
Pharmaceutical compound
From Wikipedia, the free encyclopedia
AB-103 is a minoxidil sulfotransferase stimulant which is under development for the treatment of alopecia (hair loss) as an adjunct to the hair loss drug minoxidil.[1] It is used topically.[1] The drug works by stimulating the enzyme SULT1A1 in hair follicles which converts minoxidil into its active form minoxidil sulfate and which has been found to predict minoxidil's clinical effectiveness.[1][2][3][4] It was originated by Applied Biology and is under development by Safety Shot.[1] As of February 2024, AB-103 is in phase 3 clinical trials for treatment of alopecia.[1] It has been in this stage of development since at least April 2019, but there have been no more recent updates on its development since then.[1] The chemical structure of AB-103 does not yet appear to have been disclosed.[1]
| Clinical data | |
|---|---|
| Other names | AB103 |
| Routes of administration | Topical[1] |
| Drug class | Minoxidil sulfotransferase stimulant |
